Last reviewed · How we verify

lidocaine 3.6%, menthol 1.25%

J.A.R. Laboratories · Phase 1 active Small molecule

lidocaine 3.6%, menthol 1.25% is a Small molecule drug developed by J.A.R. Laboratories. It is currently in Phase 1 development. Also known as: LidoPatch.

At a glance

Generic namelidocaine 3.6%, menthol 1.25%
Also known asLidoPatch
SponsorJ.A.R. Laboratories
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about lidocaine 3.6%, menthol 1.25%

What is lidocaine 3.6%, menthol 1.25%?

lidocaine 3.6%, menthol 1.25% is a Small molecule drug developed by J.A.R. Laboratories.

Who makes lidocaine 3.6%, menthol 1.25%?

lidocaine 3.6%, menthol 1.25% is developed by J.A.R. Laboratories (see full J.A.R. Laboratories pipeline at /company/j-a-r-laboratories).

Is lidocaine 3.6%, menthol 1.25% also known as anything else?

lidocaine 3.6%, menthol 1.25% is also known as LidoPatch.

What development phase is lidocaine 3.6%, menthol 1.25% in?

lidocaine 3.6%, menthol 1.25% is in Phase 1.

Related